Greg Moeck

Greg Moeck


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2014 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
GCG. Ralph Corey
G. Ralph Corey
HKHeidi Kabler
Heidi Kabler
PMPurvi Mehra
Purvi Mehra
SGSandeep Gupta
Sandeep Gupta
JOJ. Scott Overcash
J. Scott Overcash
WOWilliam O'RIordan
William O'RIordan
Oritavancin is a lipoglycopeptide with bactericidal activity against gram-positive bacteria. Its concentration-dependent activity and prolonged half-life allow for single-dose treatment.

11 January 2004 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
JLJing Liu
Jing Liu
MDMohammed Dehbi
Mohammed Dehbi
GMGreg Moeck
Greg Moeck
FAFrancis Arhin
Francis Arhin
PBPascale Bauda
Pascale Bauda
MDMichael DuBow
Michael DuBow

6 October 2014 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
GCG Ralph Corey
G Ralph Corey
SGSamantha Good
Samantha Good
HJHai Jiang
Hai Jiang
GMGreg Moeck
Greg Moeck
MWMatthew Wikler
Matthew Wikler
SISOLO II Investigators
SOLO II Investigators
Background. Oritavancin is a lipoglycopeptide antibiotic with rapid bactericidal activity against gram-positive bacteria. Its concentration-dependent activity and long half-life allow for single-dose treatment.

1 June 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
CRChristopher Rubino
Christopher Rubino
SBS. M. Bhavnani
S. M. Bhavnani
GMGreg Moeck
Greg Moeck
SBS. E. Bellibas
S. E. Bellibas
PAP. G. Ambrose
P. G. Ambrose
Oritavancin is a lipoglycopeptide antibiotic with activity against Gram-positive bacteria. Here we describe oritavancin population pharmacokinetics and the impact of patient-specific covariates on drug exposure variability. Concentration-time data were analyzed from two phase 3 clinical trials, SOLO I and SOLO II, in which oritavancin was administered as a single 1,200-mg dose to patients with acute bacterial skin and skin structure infections. A total of 1,337 drug concentrations from 297 patients (90% of whom had 4 or 5 pharmacokinetic samples) were available for analysis. A previously derived population model based on data from 12 phase 1, 2, and 3 oritavancin studies was applied to the SOLO data set. Alterations to the structural model were made, as necessary, based on model fit. Analyses utilized Monte Carlo parametric expectation maximization (S-ADAPT 1.5.6). The previous population pharmacokinetic model fit the data well ( r 2 = 0.972), and population pharmacokinetic parameters were estimated with acceptable precision and lack of bias. Covariate evaluations revealed statistically significant relationships between central compartment volume and age and between clearance and height; however, these relationships did not indicate a clinically relevant impact on oritavancin exposure over the range of age and height observed in the SOLO studies. The mean (coefficient of variation [CV]) area under the plasma concentration-time curve from time zero to 72 h (AUC 0–72 ) and maximum plasma concentration ( C max ) were 1,530 (36.9%) μg · h/ml and 138 (23%) μg/ml, respectively. The mean (CV) half-life at alpha phase ( t 1/2α ), t 1/2β , and t 1/2γ were 2.29 (49.8%), 13.4 (10.5%), and 245 (14.9%) hours, respectively. These analyses are the first to describe oritavancin pharmacokinetics following a single 1,200-mg dose. Covariate analyses suggested that no dose adjustments are required for renal impairment (creatinine clearance, >29 ml/min), mild or moderate hepatic impairment, age, weight, gender, or diabetes status.

15 January 2011 in Journal of Bacteriology
Verified
Journal Article
Closed access
PDF file
MSMourad Sabri
Mourad Sabri
RHRoman Häuser
Roman Häuser
MOMarc Ouellette
Marc Ouellette
JLJing Liu
Jing Liu
MDMohammed Dehbi
Mohammed Dehbi
SMSylvain Moineau
Sylvain Moineau
Streptococcus pneumoniae causes several diseases, including pneumonia, septicemia, and meningitis. Phage Dp-1 is one of the very few isolated virulent S. pneumoniae bacteriophages, but only a partial characterization is currently available. Here, we confirmed that Dp-1 belongs to the family Siphoviridae . Then, we determined its complete genomic sequence of 56,506 bp. It encodes 72 open reading frames, of which 44 have been assigned a function. We have identified putative promoters, Rho-independent terminators, and several genomic clusters. We provide evidence that Dp-1 may be using a novel DNA replication system as well as redirecting host protein synthesis through queuosine-containing tRNAs. Liquid chromatography-mass spectrometry analysis of purified phage Dp-1 particles identified at least eight structural proteins. Finally, using comprehensive yeast two-hybrid screens, we identified 156 phage protein interactions, and this intraviral interactome was used to propose a structural model of Dp-1.

1 March 2006 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
GMGeoffrey A. McKay
Geoffrey A. McKay
RRRanga Reddy
Ranga Reddy
FAFrancis Arhin
Francis Arhin
ABAdam Belley
Adam Belley
DLDario Lehoux
Dario Lehoux
AFAdel Rafai Far
Adel Rafai Far